Clinical Trial Update: Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pembrolizumab in combination with carboplatin and cabazitaxel for aggressive metastatic castration-resistant prostate cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Jevtana (cabazitaxel)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Fundacion Oncosur | Conditions: Prostate Cancer Metastatic | Phase 2 | Status: RECRUITING